Medical equipment manufacturer Distalmotion has raised $90m in a funding round led by Revival Healthcare Capital to accelerate the commercialisation of its surgical robot, Dexter, across the world.
In addition to existing investors, venture capital firm 415 Capital participated in the round.
Dexter combines the benefits of robotics and affordability of laparoscopy to create a novel approach to robotic surgery.
The product returns surgeons to the sterile field, providing direct access to patients while integrating laparoscopic workflows into the robotic setup.
It was developed with a focus on making the surgeon the central point of procedures and the aim of adding a simple and versatile setup to the market that would reduce complexity.
Distalmotion CEO Michael Friedrich said: “By addressing essential problems that operating room teams face, we can deliver on our mission to fast-track widespread adoption of robotic surgery in minimally invasive care.”
The company noted that the latest funding comes after the completion of its first clinical cases and will help it accelerate the commercial scaling of Dexter.
It also noted that procedural guidelines and training protocols for robotic surgery are being developed in leading hospitals across Europe due to the involvement of Dexter in an Early Adopter Program (EAP) and clinical studies.
With the investment support, Distalmotion will work with the US Food and Drug Administration (FDA) regarding a US submission.
Distalmotion incoming chairman and Revival chairman Rick Anderson said: “The market is overdue for a fundamentally new approach to robotic surgery, where the mindset needs to be about ‘the surgeon’s robot,’ not moulding ‘the robot’s surgeon’.
“Dexter is designed to work the way surgeons and operating room (OR) teams work: patient-focused and user-centric, providing necessary patient access and optimal tools for every step of the way.”